ClinConnect ClinConnect Logo
Search / Trial NCT01356992

Patients With High-risk Acute Coronary Syndrome Without ST-segment Elevation

Launched by EUROFARMA LABORATORIOS S.A. · May 19, 2011

Trial Information

Current as of July 06, 2025

Terminated

Keywords

Non Inferiority Phase Iii Study Low Molecular Weight Heparin Versa® (Enoxaparin Eurofarma) Clexane® (Enoxaparin Sanofi Aventis) Acute Coronary Syndrome Without St Segment Elevation

ClinConnect Summary

To be included in this study, the eligible patients must meet all criteria below:

IC signature; The research subject must agree about following all instructions and perform the procedures and study visits; Men and women over the age of 18 and below the age of 75; History of angina of rest with a minimum duration of 20 minutes in the last 24 hours at the beginning and at least for 10 days.

Patient Randomization up to 6 hours after the arrival at the emergency sector.

Evidence of NSTEMI or unstable angina due to one or more of the following criteria:

1. Dynamic alterations on the T-wave (...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • ICF signature;
  • The research subject must agree about following all instructions and perform the procedures and study visits;
  • Men and women over the age of 18 and below the age of 75;
  • History of angina of rest with a minimum duration of 20 minutes in the last 24 hours at the beginning and at least for 10 days.
  • Patient Randomization up to 6 hours after the arrival at the emergency sector.
  • * Evidence of NSTEMI or unstable angina due to one or more of the following criteria:
  • 1. Dynamic alterations on the T-wave (ST-segment depression or elevation \> 1 mm, and/or T-wave inversions which are solved at least partially when the symptoms are relieved) or 2. Unevenly ST-segment (depression or elevation) in a transitional way under continuous derivations (V1+V2 or V3+V4 or V5+V6 or D1+AVL or D2+D3+AVF) or 3. Biochemical alteration on the myocardial necrosis markers (CKMB mass, troponin T or I and CPK), with the appearance of enzymatic curve, characterizing myocardial injury or 5. Pulmonary Edema; or 6. Angina associated to murmur of mitral regurgitation; or 7. Angina with heart sound to cardiac auscultation or throes; or 8. Angina with hypotension;
  • Exclusion Criteria:
  • 12-derivation-ECG with persistent ST-segment elevation;
  • Diagnosis of angina by secondary cause (e.g., anemia, fever, hypovolemia, dehydration, use of cocaine);
  • Use of non-fractionated heparin or low-molecular weight heparin in the prior 48 to the randomization;
  • Concomitant diseases, such as severe renal failure (creatinine clearance lower than 30ml/min.) and hepatic, or other significant comorbidities under investigator judgment;
  • Recent hemorrhagic cerebrovascular accident (last 12 months);
  • Patient scheduled for cardiac surgery of myocardial revascularization;
  • Use of drugs, alcohol abuse;
  • Pregnancy or lactation;
  • Recent neurosurgery or ophthalmic surgery (last 3 months);
  • History or diagnosis of coagulopathy;
  • Medical record containing allergy, hypersensibility or intolerance to any of the drug components to be used on this study, which is judged as clinically significant in the main investigator's opinion;
  • Recent participation (last 12 months) in a clinical study.

About Eurofarma Laboratorios S.A.

Eurofarma Laboratorios S.A. is a leading pharmaceutical company based in Brazil, dedicated to the research, development, manufacturing, and marketing of innovative healthcare solutions. With a strong emphasis on quality and sustainability, Eurofarma operates across various therapeutic areas, including oncology, cardiology, and central nervous system disorders. The company is committed to advancing medical science through rigorous clinical trials and collaborations, ensuring the delivery of effective and accessible treatments to patients. Eurofarma's focus on excellence and patient-centricity positions it as a key player in the global pharmaceutical landscape.

Locations

Salvador, Bahia, Brazil

Porto Alegre, Rio Grande Do Sul, Brazil

São Paulo, , Brazil

Belo Horizonte, Minas Gerais, Brazil

São Jose Do Rio Preto, São Paulo, Brazil

São Jose Do Rio Preto, , Brazil

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials